Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

28 Feb 2014

• By Cathy Dombrowski

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.

Penalties for misbranding drugs need to be tougher in order to combat counterfeiting, FDA Deputy Commissioner for Global Regulatory Operations and Policy Howard Sklamberg told the House Energy and Commerce Subcommittee on Oversight and Investigations Feb. 27.

If counterfeiting is charged as an intellectual property offense (trafficking in counterfeit goods), the maximum prison term is 20 years...